Oncology and anti-aging are two of the most discussed topics in the world of medicine. Dr. Mikhail Blagosklonny has spent his life and career dedicated to both of those fields of Oncology and Biogerontology.Dr. Mikhail Blagosklonny is of Russian origins. He was born in Russia, and he also achieved his higher education in St. Petersburg as he attended the First Pavlov State University. His alma mater is one of the esteemed universities in the city. Dr. Mikhail Blagosklonny earned both a Ph. D and an M. D. He majored in internal medicine and after that in cardiology and experimental medicine.Upon his graduation, Dr. Mikhail Blagosklonny moved to the United States of America. He started living in New York City where he took up a post at the New York Medical College. Dr. Mikhail Blagosklonny tough medicine for a few years but eventually he decided to do a transition and start doing medical research instead.

In order to accommodate the new path of his career, Dr. Mikhail Blagosklonny began working at the Ordway Research Institution during the years between 2002 and 2009. His new work place was located in Albany, New York. Dr. Mikhail Blagosklonny was holding the post of senior scientist. Over the course of his career at the Ordway Research Institution, Dr. Mikhail Blagosklonny was able to advance significantly in his research in oncology and biogerontology. However, there was only so much the institution could offer. Dr. Mikhail Blagosklonny left the Ordway Research Institution, and in 2009 he continued his studies at the Roswell Park Cancer Institute. While the Ordway Research Institute had a lot to offer Dr. Mikhail Blagosklonny in the beginning stages of his career, the Roswell Park Cancer Institute had a more streamlined and a lot fuller range of possibilities for scientists and researchers. Dr. Mikhail Blagosklonny is still donged his research at the Roswell Park.

So far, Dr. Mikhail Blagosklonny has made many a contribution to the fight against cancer. In terms of biogerontology, Dr. Mikhail Blagosklonny has become a supporter of the notion that the drug Rapamycin could potentially slow down aging. Rapamycin is a drug which is often used in therapy treatments against cancer. While the use of Rapamycin against anti-aging is still debatable, the scientific community is analyzing the idea, and there is some research under way as well.Dr. Mikhail Blagosklonny is eloquent in writing as well. He has been documenting his research for many years, and he has also written papers and articles on many topics in the fields of biogerontology and oncology as well. Dr. Mikhail Blagosklonny started working as an editor in chief a handful of years ago when the online medical journal of Oncotarget launched. Not only that, but Dr. Mikhail Blagosklonny has been doing peer reviews as an editor for other j=journals such as Cell Cycle and Aging. Over the course of his career, there have been more than a hundred original publications with the name of Dr. Mikhail Blagosklonny under it as he has become a prolific editorial writer as well.